Raymond James Financial
ORIC icon

Raymond James Financial’s Oric Pharmaceuticals ORIC Stock Holding History

Raymond James Financial’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-984
Closed -$9.99K – 6195
2025
Q2 		$9.99K Buy
+984
New +$6.61K ﹤0.01% 5928

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Raymond James Financial's ORIC Position: Q3 2025 in Review

Raymond James Financial sold out of Oric Pharmaceuticals (ORIC) in Q3 2025, closing a stake of 984 shares — an estimated $9.99K sold.

Raymond James Financial first reported a position in ORIC in Q2 2025 and held it in 1 quarter. The position peaked at $9.99K in Q2 2025. 152 funds tracked by Wall St. Rank hold ORIC as of Q3 2025.

  • Raymond James Financial reported no remaining Oric Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 984 Oric Pharmaceuticals shares in Q3 2025, an estimated $9.99K.
  • Raymond James Financial first reported a position in Oric Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Oric Pharmaceuticals position peaked at $9.99K in Q2 2025.
  • 152 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.